A patient with multiple myeloma, amyloidosis and light-chain deposition disease in kidneys with a long survival

Acta Haematologica

Volumn 101, Issue 4, 1999, Pages 202-205

  Christou, Leonidas ^a   Hatzimichael, Eleftheria Chr ^a   Sotsiou Candila, Florentia ^b   Siamopoulos, Konstantinos ^a   Bourantas, Konstantinos L ^a,c  

^a UNIVERSITY OF IOANNINA   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

^c Department of Hematology ^*  (Greece)

Author keywords

Amyloidosis; Interferon 2b; Light chain deposition disease; Long survival; Multiple myeloma

Indexed keywords

ALPHA2B INTERFERON; IMMUNOGLOBULIN LIGHT CHAIN; MELPHALAN; PREDNISONE;

ADULT; AMYLOIDOSIS; ARTICLE; CASE REPORT; HUMAN; KIDNEY DISEASE; MAINTENANCE THERAPY; MALE; MULTIPLE MYELOMA; NEPHROTIC SYNDROME; PRIORITY JOURNAL; SURVIVAL;

ADULT; AMYLOIDOSIS; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; INTERFERON-ALPHA; MALE; MELPHALAN; MULTIPLE MYELOMA; NEPHROTIC SYNDROME; PREDNISONE; REMISSION INDUCTION; SURVIVORS;

EID: 0032807768     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000040954     Document Type: Article

References (18)

1. Kyle RA: Multiple myeloma: review of 869 cases. Mayo Clin Proc 1975;50:29-40.
2. Hewell GM, Alexanian R: Multiple myeloma in young persons. Ann Intern Med 1976;84: 441-443.
3. WHO-IUIS Nomenclature Sub Committee: Nomenclature of amyloid and amyloidosis. Bull WHO 1993;71:105-111.
4. Glenner GG, Terry W, Harada M, Isersky C, Page D: Amyloid fibril proteins: Proof of homology with immunoglobulin light chains by sequence analyses. Science 1971;172:1150-1151.
5. Kyle RA, Bayrd ED: Amyloidosis: review of 236 cases. Medicine 1975;54:271-299.
6. Breathnach SM, Black MM: Systemic amyloidosis and the skin: A review with special emphasis on clinical features and therapy. Clin Exp Dermatol 1979;4:517-536.
7. Piette WW: Myeloma paraproteinemias and the skin. Med Clin North Am 1986;70:155-176.
8. Yood RA, Skinner M, Rubinow A, Talarico L, Cohen AS: Bleeding manifestations in 100 patients with amyloidosis. JAMA 1983;249: 1322-1324.
9. Alexanian R, Fraschini G, Smith L: Amyloidosis in multiple myeloma or without apparent cause. Arch Intern Med 1984;144:2158-2160.
10. Ganeval D, Noel LH, Preud' Homme JL, Droz D, Grunfeld JP: Light chain deposition disease: Its relation with AL type amyloidosis. Kidney Int 1984;26:1-9.
11. Cohen JJ, Harrington JT, Kassirer JP, Madias NE (eds): Light chain nephropathy. Nephrology Forum. Kidney Int 1985;27:582-592.
12. Buxbaum JN, Chuba JV, Hellman GC, Solomon A, Gallo G: Monoclonal immunoglobin disease: Light chain and light and heavy chain deposition diseases and their relation to light chain amyloidosis. Ann Intern Med 1990;112: 455-464.
13. Buxbaum J: Mechanisms of disease monoclonal immunoglobulin deposition. Amyloidosis, light chain deposition disease and light and heavy deposition disease. Hematol Oncol Clin North Am 1992;6:323-346.
14. Noel LH, Droz D, Ganeval D, Grunfeld JP: Renal granular monoclonal light chain deposits morphological aspects in 11 cases. Clin Nephrol 1984;21:263-269.
15. Jacquot C, Saint-André JP, Touchard G, Nochy D, D'Auzac de Lamartinie C, Oriol R, Druet P, Bariety J: Association of systemic light chain deposition disease and amyloidosis: A report of three patients with renal involvement. Clin Nephrol 1985;24:93-98.
16. Maeda K, Abesamis CM, Kuhn LM, Hyun BH: Multiple myeloma in childhood: Report of a case with breast tumors as a presenting manifestation. Am J Clin Pathol 1973;60:552-558.
17. Shustik C, Bergsagel DE, Pruzanski W: κ and λ light chain disease: Survival rates and clinical manifestations. Blood 1976;48:41-51.
18. The Nordic Myeloma Study Group: Interferon-a2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. Ann Intern Med 1996;124:212-222.